May 26 Quick Takes: Carmot raises upsized $150M series E
Plus: PFS benefit for Imfinzi, Lynparza in endometrial cancer and updates from TScan and Cedars Sinai
Deep Track Capital led an up-sized $150 million series E financing in Carmot Therapeutics Inc., which will put the money towards its pipeline of obesity and diabetes assets. 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, RA Capital Management, Millennium Management, TCGX, The Column Group, Venrock Healthcare Capital Partners and Willett Advisors participated in the financing.
AstraZeneca plc (LSE:AZN; NASDAQ:AZN) said Imfinzi durvalumab plus Lynparza olaparib and Imfinzi alone both significantly improved progression-free survival in the global Phase III DUO-E study to treat newly diagnosed advanced or recurrent endometrial cancer. It’s the first such trial of an immunotherapy and PARP inhibitor to demonstrate a clinical benefit in the setting. AZ is developing Lynparza with Merck & Co. Inc. (NYSE:MRK)...